RxDoctor Payments Data

Gina Cabela, MD

Family Medicine · Dumont, NJNPI 1225221278

Payments from drug & device makers

$2,787in general payments, 2019–2025

Across 194 payments — averaging $14.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$613
  • AstraZeneca$587
  • Boehringer Ingelheim$296
  • Lilly USA, LLC$262
  • Merck$180
  • GSK$163
  • plus $685 from 9 others

What the payments were for

  • Food & beverage$2,76799%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,787 in reported general payments places this provider in the 80th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$37,840
Medicare patients
125
Services billed
421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$15,673
FarxigaDapagliflozin Propanediol11$10,312
Atorvastatin Calcium103$1,367
Losartan Potassium43$559
Amlodipine Besylate50$324
Albuterol Sulfate HfaAlbuterol Sulfate14$312
Metformin Hcl ErMetformin Hcl24$207
Enalapril Maleate16$206
Rosuvastatin Calcium29$191
Metformin Hcl28$178
Lisinopril24$178
Valsartan15$164
Levothyroxine Sodium16$145
Metoprolol Succinate15$102
Simvastatin14$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$613$15,67316 claims
AstraZenecaFarxiga$587$10,31211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Dumont

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →